GeneSightRx will now measure and analyze 50 clinically important genetic variants of six genes that affect patients’ response to medications prescribed in psychiatric medicine.
The enhanced six-gene Web-based therapeutic decision support product analyzes genetic variants which may affect a patient’s ability to tolerate or respond to psychotropic medications.
The gene variations are then analyzed against 26 FDA-approved drugs to help physicians select the appropriate psychotropic medications for each patient.
In addition to the CYP2C9 gene, GeneSightRx analyzes genetic variations in the CYP2D6, CYP2C19, and CYP1A2 genes, as well as the serotonin transporter gene SLC6A4 and the serotonin 2A receptor gene 5HTR2A.
AssureRx president and CEO James Burns said our goal is to build the leading medical informatics company providing pharmacogenetic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders.
AssureRx Health senior vice president of Sales & Commercial Programs John Bellano said enhancing GeneSightRx with the CYP2C9 gene now provides physicians with even more information about their patients’ unique genetic fingerprint, allowing them to make more informed medication choices for each individual patient.